Gene Logic’s Ascenta ( Biomarker database) References


Following are a list of references for our Ascenta ( Biomarker database) arranged in chronological order. We are adding public data based on customer feedback. Please do let us know if there are specific data sets/ diseases you would like us to add.

**************************************************************************************

2012

****************************************************************************************

Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: A Gynecologic Oncology Group Study

C Aghajanian, MW Sill, AA Secord, MA Powell… – Gynecologic …, 2012 – Elsevier
 CR IPT ACCEPTED MANUSCRIPT characterize the expression level of PARP1 and PARP1
related genes using a microarray expression generated from well annotated diseased and normal
tissue samples has been performed (ASCENTA database; Gene Logic, Gaithersburg). 

**************************************************************************************

2011

****************************************************************************************

BIOMARKER FOR MICRODOMAIN DISORDER

K Higashi… – EP Patent 2,343,554, 2011 – freepatentsonline.com
 Example 4 (Expression Analysis of GM2A Gene in Obese Patient). Distribution of
expression of GM2A gene in a human normal tissue was examined using Ascenta
of Gene Logic Inc. , which is a commercially available database 
K Vouk, T Smuc, C Guggenberger… – The Journal of Steroid …, 2011 – Elsevier
 These were obtained from the Genelogic ASCENTA System (http://www.genelogic.com),
a commercial database that provides microarray gene-expression profiles from
clinically-relevant normal and diseased human tissue sample sets. 
M Kamarinos… – asbmb.org.au
 GeneLogic’s Affymetrix subscription database (ASCENTA system; www.genelogic.com) is  One
such organisation is the Microarray Gene Expression Data society (MGED, http://www.mged.org) which
has developed guidelines for reporting the microarray results known as 

**************************************************************************************

2010

****************************************************************************************

A NOVEL ADIPOKINE GM2AP IMPAIRS INSULIN SIGNALING

K Higashi, T Mikami, T Yamada… – Biochemical and …, 2010 – Elsevier
 2.8. Gene logic ASCENTA database.  The ASCENTA System from Gene Logic Inc., allowed us
to immediately access microarray expression data from diseased and normal tissue samples
to facilitate discovery and validation of GM2AP as a biomarker or drug target. 
***************

UPREGULATION OF POLY (ADP-RIBOSE) POLYMERASE-1 (PARP1) IN TRIPLE-NEGATIVE BREAST CANCER AND OTHER PRIMARY HUMAN TUMOR TYPES

V Ossovskaya, IC Koo, EP Kaldjian… – Genes & …, 2010 – gan.sagepub.com
 These results, as well as attendant pathology and clinical data, were annotated within sample
gene expression and analysis databases for both population-based and individual sample-based
studies (Ascenta, BioExpress Systems, Gene Logic; Cureline BioPathology 

**************************************************************************************

2009

****************************************************************************************

D Puzzo, A Staniszewski, SX Deng… – The Journal of …, 2009 – neuro.cjb.net
 5 (PDE5), an enzyme expressed in several brain regions associated with cognitive function, such
as the hippocampus, cortex, and cerebellum (Van Staveren et al., 2003, 2004) (see also, for
human brain, Gene Logic’s ASCENTA System) (M. Sakurai, personal communication). 

**************************************************************************************

2008

***************************************************************************************

Z Yan, H Zou, F Tian, JR Grandis, AJ Mixson… – Molecular cancer …, 2008 – AACR
 Determination of Gene Expression Profiles in Human Cancer Specimens. The
ASCENTA System from Gene Logic was used. Human clinical specimens were
collected and verified by the vendor’s board-certified pathologists 

**************************************************************************************

2007

****************************************************************************************

BREAST CANCER SCREENING AND TREATMENT METHODS

RM Coopersmith, DW White, S Jin… – US Patent App. 11/ …, 2007 – Google Patents
 LOUIS, MO 63105 (73) Assignee: Gene Logic Inc., Gaithersburg, MD (US) (21)
Appl.No.: 11/935,870 (22) Filed: Nov. 6, 2007 Related US Application Data (60)
Provisional application No. 60/865,094, filed on Nov. 9, 2006. (51) Int. CI. 
************************

Bioinformatics approaches in the study of cancer

DA Hanauer, DR Rhodes… – Current molecular …, 2007 – ingentaconnect.com
 Gene Logic also offers their ASCENTA® System [20] which contains about 8,700 Affymetrix
GeneChip® mouse, human, and rat arrays.  projects ranging from management of clinical trials
to tools for analysis of gene expression data.  [19] http://www.genelogic.com/docs/pdfs 

********************************************************************************

2006

**********************************************************************************

THE ROLE OF BIOINFORMATICS IN GENOMIC MEDICINE

AHC Kampen… – Cardiovascular Research, 2006 – Springer
 Ascenta Gene expression database www.genelogic.com Bodymap Data bank of expression
bodymap.ims.u-tokyo.ac.jp information CaGE Cardiac Gene Expression http://www.cage.wbmei.jhu.
edu knowledge base EBI European Bioinformatics http://www.ebi.ac.uk (SRS, MIAME, Institute 

RON IN BREAST DEVELOPMENT AND CANCER

SE Waltz – 2006 – DTIC Document
 Fig. 1 is given in the figure legend. With respect to cancer cell lines, Table 2 lists
those that are positive and negative for RON expression on the basis of flow cytometry,
Western blotting, and Ascenta data (Gene Logic). Of the 
***************

THERAPEUTIC IMPLICATIONS OF A HUMAN NEUTRALIZING ANTIBODY TO THE MACROPHAGE-STIMULATING PROTEIN RECEPTOR TYROSINE KINASE (RON), A C-MET FAMILY MEMBER

JM O’Toole, KE Rabenau, K Burns, D Lu… – Cancer research, 2006 – AACR
 Fig. 1 is given in the figure legend. With respect to cancer cell lines, Table 2 lists
those that are positive and negative for RON expression on the basis of flow cytometry,
Western blotting, and Ascenta data (Gene Logic). Of the 

***************************************************************************

2004

*****************************************************************************

The ASCENTA system reveals candidate cancer treatment targets by their co-regulation across the human body: Using a known target, CDC2, to seed discovery

R Nadimpalli, C Coberley… – … of the American …, 2004 – aacrmeetingabstracts.org
 regulated in-phase with it. To determine the extent of cdc2 expression across human
tissues we utilized the ASCENTA System TM , an integrated human biological database
developed at Gene Logic Inc. Data from over 800 tissue 
*******************************

[PDF] Report Match/X™, A Gene Expression Pattern Recognition Algorithm Used to Identify Genes which may be Related to CDC2 Function and Cell Cycle …

C Coberley, M Elashoff… – Cell Cycle, 2004 – psychepharmaceuticals.com
 Drive; Gaithersburg, Maryland 20879 USA; Tel.: 240.364.6227; Fax: 240.364.6262; Email:
lmertz@genelogic.com Received  sample sets used for Match/X™ validation were derived from
the ASCENTA™ System, an inte- grated biological knowledgebase from Gene Logic Inc. 

*********************************

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s